130 related articles for article (PubMed ID: 29623996)
1. Ibrutinib and antimicrobial therapy in a heavily pretreated patient with chronic lymphocytic leukaemia and disseminated cutaneous non-tuberculous mycobacterial infection: successful surgery-free approach.
Maddy LE; O'Brien DP; Campbell PJ
Intern Med J; 2018 Apr; 48(4):477-479. PubMed ID: 29623996
[No Abstract] [Full Text] [Related]
2. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
[TBL] [Abstract][Full Text] [Related]
3. BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
Visentin A; Imbergamo S; Scomazzon E; Pravato S; Frezzato F; Bonaldi L; Pizzi M; Vio S; Gregianin M; Burei M; Facco M; Semenzato G; Piazza F; Trentin L
Br J Haematol; 2019 Apr; 185(1):193-197. PubMed ID: 29974955
[No Abstract] [Full Text] [Related]
4. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Michallet AS; Dilhuydy MS; Subtil F; Rouille V; Mahe B; Laribi K; Villemagne B; Salles G; Tournilhac O; Delmer A; Portois C; Pegourie B; Leblond V; Tomowiak C; de Guibert S; Orsini F; Banos A; Carassou P; Cartron G; Fornecker LM; Ysebaert L; Dartigeas C; Truchan Graczyk M; Vilque JP; Aurran T; Cymbalista F; Lepretre S; Lévy V; Nguyen-Khac F; Le Garff-Tavernier M; Aanei C; Ticchioni M; Letestu R; Feugier P
Lancet Haematol; 2019 Sep; 6(9):e470-e479. PubMed ID: 31324600
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
Manda S; Dunbar N; Marx-Wood CR; Danilov AV
Br J Haematol; 2015 Sep; 170(5):734-6. PubMed ID: 25716177
[No Abstract] [Full Text] [Related]
6. Invasive aspergillosis with pulmonary and central nervous system involvement during ibrutinib therapy for relapsed chronic lymphocytic leukaemia: case report.
Peri AM; Bisi L; Cappelletti A; Colella E; Verga L; Borella C; Foresti S; Migliorino GM; Gori A; Bandera A
Clin Microbiol Infect; 2018 Jul; 24(7):785-786. PubMed ID: 29427802
[No Abstract] [Full Text] [Related]
7. Splenic rupture following temporary cessation of ibrutinib.
Dutton D; Roach H; Lowry L
Br J Haematol; 2017 Nov; 179(3):361. PubMed ID: 28737217
[No Abstract] [Full Text] [Related]
8. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
[TBL] [Abstract][Full Text] [Related]
9. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Hallek M; Kay NE; Osterborg A; Chanan-Khan AA; Mahler M; Salman M; Wan Y; Sun S; Zhuang SH; Howes A
Future Oncol; 2015; 11(1):51-9. PubMed ID: 24901734
[TBL] [Abstract][Full Text] [Related]
10. HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.
Innocenti I; Morelli F; Autore F; Corbingi A; Pasquale R; Sorà F; Pompili M; Laurenti L
Leuk Lymphoma; 2019 May; 60(5):1340-1342. PubMed ID: 30730231
[No Abstract] [Full Text] [Related]
11. Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia.
Tam CS; Kimber T; Seymour JF
Br J Haematol; 2017 Mar; 176(5):829-831. PubMed ID: 26915463
[No Abstract] [Full Text] [Related]
12. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
[TBL] [Abstract][Full Text] [Related]
13. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
Woyach JA
Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693
[No Abstract] [Full Text] [Related]
14. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia.
Rider TG; Grace RJ; Newman JA
Br J Haematol; 2016 Apr; 173(2):326-7. PubMed ID: 26195269
[No Abstract] [Full Text] [Related]
16. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
Sharman JP; Farber CM; Mahadevan D; Schreeder MT; Brooks HD; Kolibaba KS; Fanning S; Klein L; Greenwald DR; Sportelli P; Miskin HP; Weiss MS; Burke JM
Br J Haematol; 2017 Feb; 176(3):412-420. PubMed ID: 27982425
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous Mycobacterium chelonae infection in chronic lymphocytic leukaemia.
Dungarwalla M; Field-Smith A; Jameson C; Riley U; Chapman A; Bunker CB; Dearden CE; Matutes E
Haematologica; 2007 Jan; 92(1):e5-6. PubMed ID: 17405741
[No Abstract] [Full Text] [Related]
18. Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia--response to Rider et al.
Danilov AV
Br J Haematol; 2016 Apr; 173(2):327-8. PubMed ID: 26195155
[No Abstract] [Full Text] [Related]
19. Ibrutinib: better combined with other drugs?
Ghia P
Lancet Oncol; 2014 Sep; 15(10):1043-4. PubMed ID: 25150799
[No Abstract] [Full Text] [Related]
20. Leptomeningeal Carcinomatosis in Chronic Lymphocytic Leukemia: A Case Report and Review of the Literature.
Naydenov AV; Taylor LP
Oncologist; 2019 Sep; 24(9):1237-1245. PubMed ID: 30842245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
